Pfizer (PFE) Cash from Operations Growth (3y) (2012 - 2026)
Pfizer (PFE) Cash from Operations Growth (3y) (2012 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Ops. Growth (3y) (Qtr) |
| 1 |
Gsk |
96,436,181.12 Bn |
96,436,176.16 Bn |
7.76 Bn |
73.44% |
| 2 |
Eli Lilly |
1,017.30 Bn |
1,012.01 Bn |
16.22 Bn |
45.52% |
| 3 |
Johnson & Johnson |
579.61 Bn |
557.55 Bn |
15.96 Bn |
-8.27% |
| 4 |
AbbVie |
402.30 Bn |
392.96 Bn |
10.78 Bn |
-2.98% |
| 5 |
Merck |
294.24 Bn |
288.59 Bn |
12.09 Bn |
43.03% |
| 6 |
Amgen |
191.82 Bn |
179.78 Bn |
5.87 Bn |
27.18% |
| 7 |
Gilead Sciences |
155.93 Bn |
148.21 Bn |
5.52 Bn |
13.41% |
| 8 |
Pfizer |
149.05 Bn |
136.28 Bn |
-1.21 Bn |
29.22% |
| 9 |
Bristol Myers Squibb |
116.33 Bn |
105.88 Bn |
8.07 Bn |
-28.10% |
| 10 |
Novartis Ag |
112.59 Bn |
111.90 Bn |
- |
- |
| Date | Value |
|---|
| Mar 29, 2026 |
29.22% |
| Sep 28, 2025 |
-39.40% |
| Jun 29, 2025 |
-27.47% |
| Mar 30, 2025 |
-29.06% |
| Sep 29, 2024 |
-39.35% |
| Jun 30, 2024 |
-29.22% |
| Mar 31, 2024 |
-37.84% |
| Oct 1, 2023 |
-18.41% |
| Jul 2, 2023 |
-31.36% |
| Apr 2, 2023 |
-17.46% |
| Oct 2, 2022 |
66.15% |
| Jul 3, 2022 |
46.26% |
| Apr 3, 2022 |
56.76% |
| Oct 3, 2021 |
72.50% |
| Jul 4, 2021 |
43.21% |
| Apr 4, 2021 |
31.78% |
| Sep 27, 2020 |
9.19% |
| Jun 28, 2020 |
11.84% |
| Mar 29, 2020 |
10.81% |
| Dec 31, 2019 |
-14.55% |
